Joachim Beck

4.2k total citations · 1 hit paper
35 papers, 2.5k citations indexed

About

Joachim Beck is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Joachim Beck has authored 35 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Public Health, Environmental and Occupational Health and 7 papers in Genetics. Recurrent topics in Joachim Beck's work include Acute Lymphoblastic Leukemia research (11 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Joachim Beck is often cited by papers focused on Acute Lymphoblastic Leukemia research (11 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Joachim Beck collaborates with scholars based in Germany, United States and Australia. Joachim Beck's co-authors include Margaret Dugan, Dieter Hoelzer, Mojca Jongen‐Lavrencic, Carlos Graux, Wim van Putten, Gregor Verhoef, Augustin Ferrant, Leo F. Verdonck, Bart J. Biemond and Marie von Lilienfeld‐Toal and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Joachim Beck

32 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Joachim Beck

Since Specialization

Citations

This map shows the geographic impact of Joachim Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joachim Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joachim Beck more than expected).

Fields of papers citing papers by Joachim Beck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joachim Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joachim Beck. The network helps show where Joachim Beck may publish in the future.

Co-authorship network of co-authors of Joachim Beck

This figure shows the co-authorship network connecting the top 25 collaborators of Joachim Beck. A scholar is included among the top collaborators of Joachim Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joachim Beck. Joachim Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia 2025 ·Leukemia & lymphoma ·Fabian Lang, Andreas Voß, Guido Kobbe, Christian Junghanß, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, (unknown), Vladan Vučinić, Boris Böll, Max S. Topp, (unknown), Hubert Serve, Nicola Goekbuget, Oliver G. Ottmann, Roman Pfeifer	0
2	Transdisciplinary Discourses on Cross-Border Cooperation in Europe 2019 ·Peter Lang B eBooks ·(unknown), (unknown), Joachim Beck	16
3	Asparaginase activities during intensified treatment with pegylatedE. coliasparaginase in adults with newly-diagnosed acute lymphoblastic leukemia 2019 ·Leukemia & lymphoma ·Claudia Lanvers‐Kaminsky, (unknown), Maria Eveslage, Joachim Beck, Thomas Köhnke, Sonja Martin, Maike de Wit, Bernd M. Spriewald, (unknown), Dieter Hoelzer, Joachim Boos, Nicola Gökbuget	15
4	Cross-Border Cooperation: Challenges and Perspectives for the Horizontal Dimension of European Integration 2018 ·SHILAP Revista de lepidopterología ·Joachim Beck	1
5	Cross-Border Cooperation: Challenges and Perspectives for the Horizontal Dimension of European Integration 2018 ·SHILAP Revista de lepidopterología ·Joachim Beck	1
6	Cross-Border Cooperation: Challenges and Perspectives for the Horizontal Dimension of European Integration 2018 ·SHILAP Revista de lepidopterología ·Joachim Beck	1
7	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors 2013 ·Investigational New Drugs ·Sunil Sharma, Joachim Beck, Monica Mita, Sofia Paul, Margaret M. Woo, Margaret Squier, Brian Gadbaw, H. Miles Prince	29
8	High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation 2011 ·Blood ·Nicola Gökbuget, Nadežda Basara, H. Baurmann, Joachim Beck, Monika Brüggemann, H. Diedrich, (unknown), G. Hartung, Heinz‐August Horst, Andreas Hüttmann, Guido Kobbe, Ralph Naumann, Richard Ratei, Albrecht Reichle, Hubert Serve, Matthias Stelljes, Andreas Viardot, Mohammed Wattad, Dieter Hoelzer	126
9	Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients 2010 ·Head & Face Medicine ·Christian Walter, Bilal Al‐Nawas, Norbert Frickhofen, H. Gamm, Joachim Beck, (unknown), Christina Blum, Knut A. Grötz, Wilfried Wagner	63
10	High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia breakdown → 2009 ·New England Journal of Medicine ·Bob Löwenberg, Gert J. Ossenkoppele, Wim van Putten, Harry C. Schouten, Carlos Graux, Augustin Ferrant, Pieter Sonneveld, Johan Maertens, Mojca Jongen‐Lavrencic, Marie von Lilienfeld‐Toal, Bart J. Biemond, Edo Vellenga, Marinus van Marwijk Kooy, Leo F. Verdonck, Joachim Beck, Hartmut Döhner, Aloïs Gratwohl, Thomas Pabst, Gregor Verhoef	596
11	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma 2008 ·Clinical Cancer Research ·Leigh Ellis, Yan Pan, Gordon K. Smyth, Daniel J. George, Chris McCormack, (unknown), Monica Mita, Joachim Beck, Howard A. Burris, Gail Ryan, Peter Atadja, Dale Butterfoss, Margaret Dugan, Kenneth W. Culver, Ricky W. Johnstone, H. Miles Prince	244
12	Chronic stress in medical and dental education 2008 ·Medical Teacher ·Marc Schmitter, (unknown), Joachim Beck, Peter Rammelsberg	79
13	Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate 2008 ·European Urology ·Christian Walter, Bilal Al‐Nawas, Knut A. Grötz, Christian Thomas, Joachim W. Thüroff, (unknown), H. Gamm, Joachim Beck, Wilfried Wagner	125
14	PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels 2008 ·Blood ·Nicola Goekbuget, Anja Baumann, Joachim Beck, Joachim Boos, Monika Brüggemann, H. Diedrich, Andreas Hüttmann, Lothar Leimer, Thomas Lipp, Ralph Naumann, Martin Mohren, Albrecht Reichle, Kerstin Schäfer‐Eckart, Marc Schmalzing, Mathias Schmid, Norbert Schmitz, (unknown), Dieter Hoelzer	20
15	Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211) 2007 ·International Journal of Gynecological Cancer ·David S. Alberts, (unknown), Sharon P. Wilczynski, (unknown), James Moon, (unknown), Joachim Beck, Mary C. Clouser, Maurie Markman	56
16	A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies 2006 ·Clinical Cancer Research ·Francis J. Giles, Thomas Fischer, Jörge E. Cortes, Guillermo Garcia‐Manero, Joachim Beck, Farhad Ravandi, Eric Masson, P. Rae, Glen Laird, Sunil Sharma, Hagop M. Kantarjian, Margaret Dugan, Maher Albitar, Kapil N. Bhalla	264
17	Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia 2003 ·British Journal of Cancer ·S G O'Brien, (unknown), (unknown), Joachim Beck, (unknown), Catherine Dutreix, (unknown), Slavica Milosavljev, Christoph Huber, Renaud Capdeville, Thomas Fischer	125
18	A phase I study of oral uracil–ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors 2002 ·Annals of Oncology ·Frank Mayer, J. T. Hartmann, Joachim von Pawel, Joachim Beck, M. Schroeder, (unknown), (unknown), Carsten Bokemeyer	4
19	Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) 2002 ·Leukemia ·Thomas Fischer, (unknown), (unknown), (unknown), Sebastian Kreil, Joachim Beck, (unknown), Giovanni Beltrami, (unknown), Harald Gschaidmeier, Rüdiger Hehlmann, Andreas Hochhaus, Angelo Michele Carella, Christoph Huber	17
20	Der Mensch im Industriebetrieb : Gestaltung von Arbeit und Technik in der modernen Organisation 1996 ·Westdeutscher Verlag eBooks ·Joachim Beck, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact